United Therapeutics Corporation (UTHR) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $576.26, but acceptable to hold if already in. Reasons: Concentration risk — Customer: two distributors, Accredo and CVS Specialty; Concentration risk — Supplier: MannKind.
United Therapeutics develops and commercializes therapies for PAH and rare diseases, primarily through treprostinil-based products (Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram) and neuroblastoma therapy Unituxin. Substantially all treprostinil revenues flow through two... Read more
Hold if already holding. Not a fresh buy at $576.26, but acceptable to hold if already in. Reasons: Concentration risk — Customer: two distributors, Accredo and CVS Specialty; Concentration risk — Supplier: MannKind. Chart setup: RSI 55 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertwo distributors, Accredo and CVS Specialty10-K Item 1A: 'we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty'
- HIGHSupplierMannKind10-K Item 1A: 'We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement.'
- HIGHProducttreprostinil-based therapies10-K Item 1A: 'Sales of our treprostinil-based therapies — Tyvaso DPI, Nebulized Tyvaso, Remodulin, and Orenitram — comprise the vast majority of our revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $576.26, but acceptable to hold if already in. Reasons: Concentration risk — Customer: two distributors, Accredo and CVS Specialty; Concentration risk — Supplier: MannKind. Chart setup: RSI 55 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $581.78 (+1.0%), stop $552.75 (−4.3%), A.R:R -0.6:1. Score 5.6/10, moderate confidence.
Take-profit target: $581.78 (+0.8% upside). Target $581.78 (+1.0%), stop $552.75 (−4.3%), A.R:R -0.6:1. Stop-loss: $552.75.
Concentration risk — Customer: two distributors, Accredo and CVS Specialty; Concentration risk — Supplier: MannKind; Analyst target reached - limited upside remaining.
United Therapeutics Corporation trades at a P/E of 20.5 (forward 16.8). TrendMatrix value score: 5.1/10. Verdict: Hold.
21 analysts cover UTHR with a consensus score of 4.1/5. Average price target: $645.
What does United Therapeutics Corporation do?United Therapeutics develops and commercializes therapies for PAH and rare diseases, primarily through...
United Therapeutics develops and commercializes therapies for PAH and rare diseases, primarily through treprostinil-based products (Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram) and neuroblastoma therapy Unituxin. Substantially all treprostinil revenues flow through two specialty distributors (Accredo and CVS Specialty). Tyvaso DPI is manufactured solely by MannKind with no backup arrangement.